Search research articles
Contact Us
Filters
Showing results (101-110 of 474) with videos related to
Page
of 48
Sort By:
European Urology
|
July 13, 2020
Reply to Carissa E. Chu, Peter E. Lonergan, and Peter R. Carroll's Letter to the Editor re: Vasilis Stavrinides, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. Eur Urol 2020;78:443-51
Vasilis Stavrinides, Francesco Giganti, Mark Emberton, et al.
European Urology
|
August 12, 2019
Reply to Francesco Montorsi, Giorgio Gandaglia, Alberto Briganti's Letter to the Editor, re: Veeru Kasivisvanathan, Armando Stabile, Joana B. Neves, et al. Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review, Meta-analysis. Eur Urol 2019;76:284-303: The choice of diagnostic test in prostate cancer is a balance of the risks and benefits: One size may not fit all
Veeru Kasivisvanathan, Yemisi Takwoingi, Mark Emberton, et al.
BJU International
|
May 12, 2006
The beneficial effect of alfuzosin 10 mg once daily in 'real-life' practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculation
J Curtis Nickel, Mostafa Elhilali, Mark Emberton, et al.
BMJ (Clinical Research Ed.)
|
February 25, 2010
Life after prostate cancer. Time to evaluate focal therapy
Paul Cathcart, Hashim Uddin Ahmed, Caroline Moore, et al.
European Urology
|
July 27, 2020
Reply to Francesco Montorsi, Giorgio Gandaglia, Nicola Fossati, Andrea Salonia, and Alberto Briganti's Letter to the Editor re: Vasilis Stavrinides, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. Eur Urol 2020;78:443-51
Vasilis Stavrinides, Francesco Giganti, Mark Emberton, et al.
Prostate Cancer and Prostatic Diseases
|
August 18, 2018
MRI in active surveillance: a critical review
Vasilis Stavrinides, Francesco Giganti, Mark Emberton, et al.
Prostate Cancer and Prostatic Diseases
|
June 19, 2021
Prostate cancer and the human papilloma virus: causative association, role of vaccines, and the impact of the COVID-19 pandemic
Naomi Morka, Joseph M Norris, Mark Emberton, et al.
Nature Reviews. Urology
|
February 8, 2012
A biomedical engineering approach to mitigate the errors of prostate biopsy
Hashim Uddin Ahmed, Mark Emberton, Gordon Kepner, et al.
The Lancet. Oncology
|
November 18, 2008
Hormone therapy: a revolution in understanding prostate cancer
Manit Arya, Iqbal S Shergill, Philippe Grange, et al.
Urologic Oncology
|
September 7, 2010
Focal therapy for prostate cancer: fact or fiction?
Emilie Lecornet, Caroline Moore, Hashim Uddin Ahmed, et al.
Page
of 48
Search research articles
Search
Showing results (101-110 of 474) with videos related to
Sort By:
Page
of 48
European Urology
|
July 13, 2020
Reply to Carissa E. Chu, Peter E. Lonergan, and Peter R. Carroll's Letter to the Editor re: Vasilis Stavrinides, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. Eur Urol 2020;78:443-51
Vasilis Stavrinides, Francesco Giganti, Mark Emberton, et al.
European Urology
|
August 12, 2019
Reply to Francesco Montorsi, Giorgio Gandaglia, Alberto Briganti's Letter to the Editor, re: Veeru Kasivisvanathan, Armando Stabile, Joana B. Neves, et al. Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review, Meta-analysis. Eur Urol 2019;76:284-303: The choice of diagnostic test in prostate cancer is a balance of the risks and benefits: One size may not fit all
Veeru Kasivisvanathan, Yemisi Takwoingi, Mark Emberton, et al.
BJU International
|
May 12, 2006
The beneficial effect of alfuzosin 10 mg once daily in 'real-life' practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculation
J Curtis Nickel, Mostafa Elhilali, Mark Emberton, et al.
BMJ (Clinical Research Ed.)
|
February 25, 2010
Life after prostate cancer. Time to evaluate focal therapy
Paul Cathcart, Hashim Uddin Ahmed, Caroline Moore, et al.
European Urology
|
July 27, 2020
Reply to Francesco Montorsi, Giorgio Gandaglia, Nicola Fossati, Andrea Salonia, and Alberto Briganti's Letter to the Editor re: Vasilis Stavrinides, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. Eur Urol 2020;78:443-51
Vasilis Stavrinides, Francesco Giganti, Mark Emberton, et al.
Prostate Cancer and Prostatic Diseases
|
August 18, 2018
MRI in active surveillance: a critical review
Vasilis Stavrinides, Francesco Giganti, Mark Emberton, et al.
Prostate Cancer and Prostatic Diseases
|
June 19, 2021
Prostate cancer and the human papilloma virus: causative association, role of vaccines, and the impact of the COVID-19 pandemic
Naomi Morka, Joseph M Norris, Mark Emberton, et al.
Nature Reviews. Urology
|
February 8, 2012
A biomedical engineering approach to mitigate the errors of prostate biopsy
Hashim Uddin Ahmed, Mark Emberton, Gordon Kepner, et al.
The Lancet. Oncology
|
November 18, 2008
Hormone therapy: a revolution in understanding prostate cancer
Manit Arya, Iqbal S Shergill, Philippe Grange, et al.
Urologic Oncology
|
September 7, 2010
Focal therapy for prostate cancer: fact or fiction?
Emilie Lecornet, Caroline Moore, Hashim Uddin Ahmed, et al.
Page
of 48